Drug Trial Radar · NCT06950086
Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Jan 2, 2024
Primary completion
Sep 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- TYK Medicines, IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the safety, pharmacokinetics, and preliminary antitumor activity of TYK-00540 as monotherapy or combined with fulvestrant in advanced solid tumors.
Conditions
- HR-positive, HER2-negative Advanced Breast Cancer
Interventions
TYK-00540Drug
Increased dose cohorts from low to MTD (5mg Cohort 1;10 mg Cohort 2; 20 mg Cohort 3; 30 mg Cohort 4;40 mg Cohort 5) decreased dose cohorts for the combination (TYK-00540 30 mg+Fulvestrant Cohort 1;TYK-00540 20mg +Fulvestrant)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicity (DLT)Time frame: Within 31 days of the first dose
- Recommended dose for combination-agent escalation and single-agent expansion (RDE)Time frame: 1 year
- Adverse events (AEs)Time frame: From Baseline up to 28 days after the end of the treatment
- Objective response rate (ORR)Time frame: At least 24 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.